Changes

==References==

==References==

Barbaux, S., Niaudet, P., Gubler, M.C., Grünfeld, J.P., Jaubert, F., Kuttenn, F., Fékété, C.N., Souleyreau-Therville, N., Thibaud, E., Fellous, M., et al. (1997). Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet. 17, 467–470. PMID: 9398852

*Barbaux, S., Niaudet, P., Gubler, M.C., Grünfeld, J.P., Jaubert, F., Kuttenn, F., Fékété, C.N., Souleyreau-Therville, N., Thibaud, E., Fellous, M., et al. (1997). Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat. Genet. 17, 467–470. PMID: 9398852

Brayer, J., Lancet, J.E., Powers, J., List, A., Balducci, L., Komrokji, R., and Pinilla-Ibarz, J. (2015). WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol 90, 602–607. PMID: 25802083

*Brayer, J., Lancet, J.E., Powers, J., List, A., Balducci, L., Komrokji, R., and Pinilla-Ibarz, J. (2015). WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol 90, 602–607. PMID: 25802083

Breslow, N.E., Beckwith, J.B., Perlman, E.J., and Reeve, A.E. (2006). Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatric Blood & Cancer 47, 260–267. PMID: 16700047

*Breslow, N.E., Beckwith, J.B., Perlman, E.J., and Reeve, A.E. (2006). Age distributions, birth weights, nephrogenic rests, and heterogeneity in the pathogenesis of Wilms tumor. Pediatric Blood & Cancer 47, 260–267. PMID: 16700047

Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yeger, H., and Lewis, W.H. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60, 509–520. PMID: 2154335

*Call, K.M., Glaser, T., Ito, C.Y., Buckler, A.J., Pelletier, J., Haber, D.A., Rose, E.A., Kral, A., Yeger, H., and Lewis, W.H. (1990). Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell 60, 509–520. PMID: 2154335

Di Stasi, A., Jimenez, A.M., Minagawa, K., Al-Obaidi, M., and Rezvani, K. (2015). Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol 6. PMID: 25699052

*Di Stasi, A., Jimenez, A.M., Minagawa, K., Al-Obaidi, M., and Rezvani, K. (2015). Review of the Results of WT1 Peptide Vaccination Strategies for Myelodysplastic Syndromes and Acute Myeloid Leukemia from Nine Different Studies. Front Immunol 6. PMID: 25699052

Dohi, S., Ohno, S., Ohno, Y., Soma, G.-I., Kyo, S., and Inoue, M. (2009). Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res. 29, 4887–4891. PMID: 20032452

*Dohi, S., Ohno, S., Ohno, Y., Soma, G.-I., Kyo, S., and Inoue, M. (2009). Correlation between WT1 expression and cell proliferation in endometrial cancer. Anticancer Res. 29, 4887–4891. PMID: 20032452

Gaidzik, V.I., Schlenk, R.F., Moschny, S., Becker, A., Bullinger, L., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Döhner, H., et al. (2009). Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 113, 4505–4511. PMID: 19221039

*Gaidzik, V.I., Schlenk, R.F., Moschny, S., Becker, A., Bullinger, L., Corbacioglu, A., Krauter, J., Schlegelberger, B., Ganser, A., Döhner, H., et al. (2009). Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 113, 4505–4511. PMID: 19221039

Gessler, M., König, A., Arden, K., Grundy, P., Orkin, S., Sallan, S., Peters, C., Ruyle, S., Mandell, J., and Li, F. (1994). Infrequent mutation of the WT1 gene in 77 Wilms’ Tumors. Hum. Mutat. 3, 212–222. PMID: 8019557

*Gessler, M., König, A., Arden, K., Grundy, P., Orkin, S., Sallan, S., Peters, C., Ruyle, S., Mandell, J., and Li, F. (1994). Infrequent mutation of the WT1 gene in 77 Wilms’ Tumors. Hum. Mutat. 3, 212–222. PMID: 8019557

Haber, D.A., Sohn, R.L., Buckler, A.J., Pelletier, J., Call, K.M., and Housman, D.E. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc. Natl. Acad. Sci. U.S.A. 88, 9618–9622. PMID: 1658787

*Haber, D.A., Sohn, R.L., Buckler, A.J., Pelletier, J., Call, K.M., and Housman, D.E. (1991). Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc. Natl. Acad. Sci. U.S.A. 88, 9618–9622. PMID: 1658787

Hammes, A., Guo, J.K., Lutsch, G., Leheste, J.R., Landrock, D., Ziegler, U., Gubler, M.C., and Schedl, A. (2001). Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106, 319–329. PMID: 11509181

*Hammes, A., Guo, J.K., Lutsch, G., Leheste, J.R., Landrock, D., Ziegler, U., Gubler, M.C., and Schedl, A. (2001). Two splice variants of the Wilms’ tumor 1 gene have distinct functions during sex determination and nephron formation. Cell 106, 319–329. PMID: 11509181

Hastie, N.D. (2017). Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development 144, 2862–2872. PMID: 28811308

*Hastie, N.D. (2017). Wilms’ tumour 1 (WT1) in development, homeostasis and disease. Development 144, 2862–2872. PMID: 28811308

Hewitt, S.M., Hamada, S., McDonnell, T.J., Rauscher, F.J., and Saunders, G.F. (1995). Regulation of the Proto-oncogenes bcl-2 and c-myc by the Wilms’ Tumor Suppressor Gene WT1. Cancer Res 55, 5386–5389. PMID: 7585606

*Hewitt, S.M., Hamada, S., McDonnell, T.J., Rauscher, F.J., and Saunders, G.F. (1995). Regulation of the Proto-oncogenes bcl-2 and c-myc by the Wilms’ Tumor Suppressor Gene WT1. Cancer Res 55, 5386–5389. PMID: 7585606

Hollink, I.H.I.M., van den Heuvel-Eibrink, M.M., Zimmermann, M., Balgobind, B.V., Arentsen-Peters, S.T.C.J.M., Alders, M., Willasch, A., Kaspers, G.J.L., Trka, J., Baruchel, A., et al. (2009). Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113, 5951–5960. PMID: 19171881

*Hollink, I.H.I.M., van den Heuvel-Eibrink, M.M., Zimmermann, M., Balgobind, B.V., Arentsen-Peters, S.T.C.J.M., Alders, M., Willasch, A., Kaspers, G.J.L., Trka, J., Baruchel, A., et al. (2009). Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 113, 5951–5960. PMID: 19171881

Huff, V., and Saunders, G.F. (1993). Wilms tumor genes. Biochim. Biophys. Acta 1155, 295–306.

*Huff, V., and Saunders, G.F. (1993). Wilms tumor genes. Biochim. Biophys. Acta 1155, 295–306. PMID: 8268188

Hylander, B., Repasky, E., Shrikant, P., Intengan, M., Beck, A., Driscoll, D., Singhal, P., Lele, S., and Odunsi, K. (2006). Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol. Oncol. 101, 12–17. PMID: 16263157

Köbel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N.J., Ionescu, D.N., Rajput, A., et al. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5, e232. PMID: 19053170

*Hylander, B., Repasky, E., Shrikant, P., Intengan, M., Beck, A., Driscoll, D., Singhal, P., Lele, S., and Odunsi, K. (2006). Expression of Wilms tumor gene (WT1) in epithelial ovarian cancer. Gynecol. Oncol. 101, 12–17. PMID: 16263157

Koido, S., Homma, S., Okamoto, M., Takakura, K., Mori, M., Yoshizaki, S., Tsukinaga, S., Odahara, S., Koyama, S., Imazu, H., et al. (2014). Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res. 20, 4228–4239. PMID: 25056373

*Köbel, M., Kalloger, S.E., Boyd, N., McKinney, S., Mehl, E., Palmer, C., Leung, S., Bowen, N.J., Ionescu, D.N., Rajput, A., et al. (2008). Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 5, e232. PMID: 19053170

Krauth, M.-T., Alpermann, T., Bacher, U., Eder, C., Dicker, F., Ulke, M., Kuznia, S., Nadarajah, N., Kern, W., Haferlach, C., et al. (2015). WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 29, 660–667. PMID: 25110071

*Koido, S., Homma, S., Okamoto, M., Takakura, K., Mori, M., Yoshizaki, S., Tsukinaga, S., Odahara, S., Koyama, S., Imazu, H., et al. (2014). Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res. 20, 4228–4239. PMID: 25056373

Liu, Z., Yamanouchi, K., Ohtao, T., Matsumura, S., Seino, M., Shridhar, V., Takahashi, T., Takahashi, K., and Kurachi, H. (2014). High Levels of Wilms’ Tumor 1 (WT1) Expression Were Associated with Aggressive Clinical Features in Ovarian Cancer. Anticancer Res 34, 2331–2340. PMID: 24778040

*Krauth, M.-T., Alpermann, T., Bacher, U., Eder, C., Dicker, F., Ulke, M., Kuznia, S., Nadarajah, N., Kern, W., Haferlach, C., et al. (2015). WT1 mutations are secondary events in AML, show varying frequencies and impact on prognosis between genetic subgroups. Leukemia 29, 660–667. PMID: 25110071

Maheswaran, S., Park, S., Bernard, A., Morris, J.F., Rauscher, F.J., Hill, D.E., and Haber, D.A. (1993). Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. U.S.A. 90, 5100–5104. PMID: 8389468

*Liu, Z., Yamanouchi, K., Ohtao, T., Matsumura, S., Seino, M., Shridhar, V., Takahashi, T., Takahashi, K., and Kurachi, H. (2014). High Levels of Wilms’ Tumor 1 (WT1) Expression Were Associated with Aggressive Clinical Features in Ovarian Cancer. Anticancer Res 34, 2331–2340. PMID: 24778040

Maiti, S., Alam, R., Amos, C.I., and Huff, V. (2000). Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors. Cancer Res 60, 6288–6292. PMID: 11103785

*Maheswaran, S., Park, S., Bernard, A., Morris, J.F., Rauscher, F.J., Hill, D.E., and Haber, D.A. (1993). Physical and functional interaction between WT1 and p53 proteins. Proc. Natl. Acad. Sci. U.S.A. 90, 5100–5104. PMID: 8389468

Menke, A.L., van der Eb, A.J., and Jochemsen, A.G. (1998). The Wilms’ tumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. 181, 151–212. PMID: 9522457

*Maiti, S., Alam, R., Amos, C.I., and Huff, V. (2000). Frequent Association of β-Catenin and WT1 Mutations in Wilms Tumors. Cancer Res 60, 6288–6292. PMID: 11103785

Mikami, T., Hada, T., Chosa, N., Ishisaki, A., Mizuki, H., and Takeda, Y. (2013). Expression of Wilms’ tumor 1 (WT1) in oral squamous cell carcinoma. J. Oral Pathol. Med. 42, 133–139. PMID: 22672247

*Menke, A.L., van der Eb, A.J., and Jochemsen, A.G. (1998). The Wilms’ tumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. 181, 151–212. PMID: 9522457

Netinatsunthorn, W., Hanprasertpong, J., Dechsukhum, C., Leetanaporn, R., and Geater, A. (2006). WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 6, 90. PMID: 16606472

*Mikami, T., Hada, T., Chosa, N., Ishisaki, A., Mizuki, H., and Takeda, Y. (2013). Expression of Wilms’ tumor 1 (WT1) in oral squamous cell carcinoma. J. Oral Pathol. Med. 42, 133–139. PMID: 22672247

Paschka, P., Marcucci, G., Ruppert, A.S., Whitman, S.P., Mrózek, K., Maharry, K., Langer, C., Baldus, C.D., Zhao, W., Powell, B.L., et al. (2008). Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J. Clin. Oncol. 26, 4595–4602. PMID: 18559874

*Netinatsunthorn, W., Hanprasertpong, J., Dechsukhum, C., Leetanaporn, R., and Geater, A. (2006). WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMC Cancer 6, 90. PMID: 16606472

Pelletier, J., Bruening, W., Kashtan, C.E., Mauer, S.M., Manivel, J.C., Striegel, J.E., Houghton, D.C., Junien, C., Habib, R., and Fouser, L. (1991). Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437–447. PMID: 1655284

*Paschka, P., Marcucci, G., Ruppert, A.S., Whitman, S.P., Mrózek, K., Maharry, K., Langer, C., Baldus, C.D., Zhao, W., Powell, B.L., et al. (2008). Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J. Clin. Oncol. 26, 4595–4602. PMID: 18559874

Qi, X., Zhang, F., Wu, H., Liu, J., Zong, B., Xu, C., and Jiang, J. (2015). Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 5. PMID: 25748047

*Pelletier, J., Bruening, W., Kashtan, C.E., Mauer, S.M., Manivel, J.C., Striegel, J.E., Houghton, D.C., Junien, C., Habib, R., and Fouser, L. (1991). Germline mutations in the Wilms’ tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome. Cell 67, 437–447. PMID: 1655284

Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., et al. (2014). DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports 9, 1841–1855. PMID: 25482556

*Qi, X., Zhang, F., Wu, H., Liu, J., Zong, B., Xu, C., and Jiang, J. (2015). Wilms’ tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis. Sci Rep 5. PMID: 25748047

Rauscher, J., Beschorner, R., Gierke, M., Bisdas, S., Braun, C., Ebner, F.H., and Schittenhelm, J. (2014). WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J. Clin. Pathol. 67, 556–561. PMID: 24607494

*Rampal, R., Alkalin, A., Madzo, J., Vasanthakumar, A., Pronier, E., Patel, J., Li, Y., Ahn, J., Abdel-Wahab, O., Shih, A., et al. (2014). DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. Cell Reports 9, 1841–1855. PMID: 25482556

Riccardi, V.M., Sujansky, E., Smith, A.C., and Francke, U. (1978). Chromosomal Imbalance in the Aniridia-Wilms’ Tumor Association: 11p Interstitial Deletion. Pediatrics 61, 604–610. PMID: 208044

*Rauscher, J., Beschorner, R., Gierke, M., Bisdas, S., Braun, C., Ebner, F.H., and Schittenhelm, J. (2014). WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma. J. Clin. Pathol. 67, 556–561. PMID: 24607494

Richard, D.J., Schumacher, V., Royer-Pokora, B., and Roberts, S.G.E. (2001). Par4 is a coactivator for a splice isoform–specific transcriptional activation domain in WT1. Genes Dev. 15, 328–339. PMID: 11159913

*Riccardi, V.M., Sujansky, E., Smith, A.C., and Francke, U. (1978). Chromosomal Imbalance in the Aniridia-Wilms’ Tumor Association: 11p Interstitial Deletion. Pediatrics 61, 604–610. PMID: 208044

Rivera, M.N., Kim, W.J., Wells, J., Driscoll, D.R., Brannigan, B.W., Han, M., Kim, J.C., Feinberg, A.P., Gerald, W.L., Vargas, S.O., et al. (2007). An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315, 642–645. PMID: 17204608

*Richard, D.J., Schumacher, V., Royer-Pokora, B., and Roberts, S.G.E. (2001). Par4 is a coactivator for a splice isoform–specific transcriptional activation domain in WT1. Genes Dev. 15, 328–339. PMID: 11159913

Sano, H., Shimada, A., Tabuchi, K., Taki, T., Murata, C., Park, M., Ohki, K., Sotomatsu, M., Adachi, S., Tawa, A., et al. (2013). WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. Int. J. Hematol. 98, 437–445. PMID: 23979985

*Rivera, M.N., Kim, W.J., Wells, J., Driscoll, D.R., Brannigan, B.W., Han, M., Kim, J.C., Feinberg, A.P., Gerald, W.L., Vargas, S.O., et al. (2007). An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science 315, 642–645. PMID: 17204608

Sawada, A., Inoue, M., Kondo, O., Yamada‐Nakata, K., Ishihara, T., Kuwae, Y., Nishikawa, M., Ammori, Y., Tsuboi, A., Oji, Y., et al. (2016). Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children. Pediatric Blood & Cancer 63, 234–241. PMID: 26469989

*Sano, H., Shimada, A., Tabuchi, K., Taki, T., Murata, C., Park, M., Ohki, K., Sotomatsu, M., Adachi, S., Tawa, A., et al. (2013). WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group. Int. J. Hematol. 98, 437–445. PMID: 23979985

Shirakata, T., Oka, Y., Nishida, S., Hosen, N., Tsuboi, A., Oji, Y., Murao, A., Tanaka, H., Nakatsuka, S.-I., Inohara, H., et al. (2012). WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res. 32, 1081–1085. PMID: 22399636

*Sawada, A., Inoue, M., Kondo, O., Yamada‐Nakata, K., Ishihara, T., Kuwae, Y., Nishikawa, M., Ammori, Y., Tsuboi, A., Oji, Y., et al. (2016). Feasibility of Cancer Immunotherapy with WT1 Peptide Vaccination for Solid and Hematological Malignancies in Children. Pediatric Blood & Cancer 63, 234–241. PMID: 26469989

Summers, K., Stevens, J., Kakkas, I., Smith, M., Smith, L.L., MacDougall, F., Cavenagh, J., Bonnet, D., Young, B.D., Lister, T.A., et al. (2007). Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21, 550–551. PMID: 17205055

*Shirakata, T., Oka, Y., Nishida, S., Hosen, N., Tsuboi, A., Oji, Y., Murao, A., Tanaka, H., Nakatsuka, S.-I., Inohara, H., et al. (2012). WT1 peptide therapy for a patient with chemotherapy-resistant salivary gland cancer. Anticancer Res. 32, 1081–1085. PMID: 22399636

Suri, M., Kelehan, P., O’Neill, D., Vadeyar, S., Grant, J., Ahmed, S.F., Tolmie, J., McCann, E., Lam, W., Smith, S., et al. (2007). WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations. American Journal of Medical Genetics Part A 143A, 2312–2320. PMID: 17853480

*Summers, K., Stevens, J., Kakkas, I., Smith, M., Smith, L.L., MacDougall, F., Cavenagh, J., Bonnet, D., Young, B.D., Lister, T.A., et al. (2007). Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21, 550–551. PMID: 17205055

Ujj, Z., Buglyó, G., Udvardy, M., Beyer, D., Vargha, G., Biró, S., and Rejtő, L. (2016). WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors. Pathol. Oncol. Res. 22, 217–221. PMID: 26531831

*Suri, M., Kelehan, P., O’Neill, D., Vadeyar, S., Grant, J., Ahmed, S.F., Tolmie, J., McCann, E., Lam, W., Smith, S., et al. (2007). WT1 mutations in Meacham syndrome suggest a coelomic mesothelial origin of the cardiac and diaphragmatic malformations. American Journal of Medical Genetics Part A 143A, 2312–2320. PMID: 17853480

Virappane, P., Gale, R., Hills, R., Kakkas, I., Summers, K., Stevens, J., Allen, C., Green, C., Quentmeier, H., Drexler, H., et al. (2008). Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J. Clin. Oncol. 26, 5429–5435. PMID: 18591546

*Ujj, Z., Buglyó, G., Udvardy, M., Beyer, D., Vargha, G., Biró, S., and Rejtő, L. (2016). WT1 Expression in Adult Acute Myeloid Leukemia: Assessing its Presence, Magnitude and Temporal Changes as Prognostic Factors. Pathol. Oncol. Res. 22, 217–221. PMID: 26531831

Yang, L., Han, Y., Saiz, F.S., and Minden, M.D. (2007). A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868–876. PMID: 17361230

 

*Yang, L., Han, Y., Saiz, F.S., and Minden, M.D. (2007). A tumor suppressor and oncogene: the WT1 story. Leukemia 21, 868–876. PMID: 17361230

== Notes ==

== Notes ==